KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Change in Receivables: 2016-2024

Historic Change in Receivables for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Dec 2024 value amounting to $162.6 million.

  • Amneal Pharmaceuticals' Change in Receivables rose 455.83% to $77.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $138.8 million, marking a year-over-year increase of 144.44%. This contributed to the annual value of $162.6 million for FY2024, which is 228.78% up from last year.
  • Latest data reveals that Amneal Pharmaceuticals reported Change in Receivables of $162.6 million as of FY2024, which was up 228.78% from -$126.3 million recorded in FY2023.
  • In the past 5 years, Amneal Pharmaceuticals' Change in Receivables registered a high of $162.6 million during FY2024, and its lowest value of -$126.3 million during FY2023.
  • Moreover, its 3-year median value for Change in Receivables was $79.7 million (2022), whereas its average is $38.7 million.
  • In the last 5 years, Amneal Pharmaceuticals' Change in Receivables soared by 240.71% in 2021 and then plummeted by 258.42% in 2023.
  • Amneal Pharmaceuticals' Change in Receivables (Yearly) stood at -$16.8 million in 2020, then skyrocketed by 240.71% to $23.6 million in 2021, then soared by 237.48% to $79.7 million in 2022, then crashed by 258.42% to -$126.3 million in 2023, then skyrocketed by 228.78% to $162.6 million in 2024.